QNCX
Quince Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.32
+2.52%Sep 4, 2026, 12:32 UTC
Quince Therapeutics, Inc. received a notice from Nasdaq on August 31, 2026, stating that it no longer complies with the minimum bid price requirement under Rule 5450(b)(1)(A) for continued listing on the Nasdaq Global Market, and the company is evaluating options to regain compliance and has applied to transfer to the Nasdaq Capital Market.
Aug 27, 2026, 00:00 UTC
Charles Ryan departed as President of Quince Therapeutics, Inc., effective September 8, 2026, and is eligible for severance benefits under his Executive Change in Control and Severance Agreement dated September 1, 2023.
Aug 14, 2026, 12:00 UTC
Quince Therapeutics completed the acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to its pipeline.
Source:Aug 14, 2026, 00:00 UTC
Quince Therapeutics completed a private placement raising $115 million in gross proceeds, with potential additional proceeds of up to $83 million from warrant exercise.
Aug 14, 2026, 00:00 UTC
Quince Therapeutics reported a net loss of $75.5 million for Q2 2026, with diluted EPS of -$12.31.